An Over View of the Continuation of the Work of the Mustard Consortium for the Use of the Free and Liposome Encapsulated Antioxidants as a Counter Measure to Mustards

Abstract : The Mustard Consortium (MC) consists of Amaox, Ltd., University of Michigan, and Center for Blood Research, East Tennessee State University, Meharry Medical College and Institute for Chemical Defense. It was developed in order to take advantage of the core competencies of each investigator and institution; as well as creating a learning organization. The creation of this type of organization has allowed us to have an unparallel insight into the pathophysiology of mustards; as well as redox regulated mediated pathways that have much larger implication in the pathogenesis of disease. The MC has used a systemic approach for the elucidation of the pathophysiology of the mustard analogue CEES (2-chloroethyl ethyl sulfur); and the development of methods of intervention (potential treatments). Both in vitro and in vivo models were used by the various investigators. One investigator used human primary myeloid cells for his investigation. The success of this approach will be evident to the reader in examination of the methods of interventions that have been developed, and will continue to evolve. It is anticipated that of these several methods of experimental intervention a few will be developed into treatment regimen.